Baldwin Wealth Partners LLC MA Cuts Stock Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Baldwin Wealth Partners LLC MA trimmed its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 0.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 49,570 shares of the company’s stock after selling 125 shares during the period. Baldwin Wealth Partners LLC MA owned about 0.10% of Axsome Therapeutics worth $4,194,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Axsome Therapeutics in the 2nd quarter worth approximately $27,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Axsome Therapeutics in the second quarter worth $47,000. KBC Group NV boosted its holdings in Axsome Therapeutics by 40.5% during the 4th quarter. KBC Group NV now owns 1,336 shares of the company’s stock valued at $113,000 after acquiring an additional 385 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Axsome Therapeutics by 22.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company’s stock valued at $156,000 after acquiring an additional 318 shares during the period. Finally, Moors & Cabot Inc. bought a new position in Axsome Therapeutics during the 3rd quarter worth approximately $200,000. Institutional investors own 81.49% of the company’s stock.

Wall Street Analysts Forecast Growth

AXSM has been the subject of a number of analyst reports. StockNews.com raised Axsome Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th. Royal Bank of Canada increased their price target on shares of Axsome Therapeutics from $130.00 to $131.00 and gave the company an “outperform” rating in a research report on Friday, October 4th. Truist Financial boosted their price objective on shares of Axsome Therapeutics from $150.00 to $180.00 and gave the company a “buy” rating in a research report on Monday, January 13th. William Blair reiterated an “outperform” rating on shares of Axsome Therapeutics in a report on Friday. Finally, Needham & Company LLC restated a “buy” rating and set a $133.00 price target on shares of Axsome Therapeutics in a report on Monday, January 13th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $130.69.

Axsome Therapeutics Price Performance

AXSM stock opened at $105.03 on Monday. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44. The firm has a market capitalization of $5.09 billion, a price-to-earnings ratio of -16.09 and a beta of 1.04. The firm has a 50 day moving average price of $92.64 and a 200-day moving average price of $90.15. Axsome Therapeutics, Inc. has a 52-week low of $64.11 and a 52-week high of $105.00.

Axsome Therapeutics (NASDAQ:AXSM) last released its earnings results on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative return on equity of 158.36% and a negative net margin of 91.87%. The business had revenue of $104.76 million for the quarter, compared to the consensus estimate of $98.71 million. During the same period in the previous year, the company posted ($1.32) earnings per share. Equities research analysts forecast that Axsome Therapeutics, Inc. will post -4.73 EPS for the current fiscal year.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.